美迪西展位#104

类药产生与药代趋势学（DMPK）关键探讨类药的吸纳、分布不均、产生和脂肪代谢的动态数据的过程 与无规律，评估报告格式类药的 DMPK优点对类药的企业早期发展和往后临床医药学精准性的定位用药指导至关很主要。DMPK是桥接类药学学、毒理学、类药学、类药化学上的、甚至是变为医药学和精准性的定位医药学的很主要中介。

第26届國際口服抗癫痫制剂及电学物质脏东西产生转化协会美式会仪(ISSX)将于2021年九月份20日至18祝日美式夏威夷召开大会，会仪内部适用于口服抗癫痫制剂产生转化、药代动力系统学、临床药理学药理学学、生物制品剖析和口服抗癫痫制剂毒理学等范畴。國際口服抗癫痫制剂及电学物质脏东西产生转化协会(International Society for the Study of Xenobiotics，ISSX)是口服抗癫痫制剂产生转化研究分析的最好科研讨论组建一个，重要专注于于全球最大规模内专业对口口服抗癫痫制剂与电学物质脏东西产生转化管理方面的科研讨论交流学习和國際进行合作。美迪西邀请參加此前大会，美迪西成立人&CEO陈春麟医生与美迪西DMPK医生们希望与您欢聚一堂在108号标摊。

时间 | 9.15-9.18
地点 | Hilton Hawaiian Village Waikiki Beach Resort, Honolulu
美迪西展位  | 104，不见不散！

为了展示美迪西创新实力和技术服务平台最新进展，美迪西药代动力学/毒代动力学 (DMPK/TK) 负责人蒋品博士将以海报 (Poster) 形式分享以下主题的精彩内容：
Title: Enhancing Drug - Drug Interaction Prediction by Integrating Physiologically- Based Pharmacokinetic Model with Fraction Metabolized by CYP3A4
Session Time: Wednesday, September 18, 2024 12:30‒2:30 PM
Location: Poster Session 3
Poster Number: P270
Presenting Author: Dr. Pin Jiang, Senior Director of DMPK at Medicilon

ISSX现场美迪西专家

Dr. Pin Jiang Senior Director of DMPK

Dr. Pin Jiang holds a Ph.D. from China Pharmaceutical University in collaboration with School of Pharmacy, Fudan University. Dr. Jiang is postdoctoral fellow in DMPK and Pharmacometrics at Fudan University, specializes in the development of DMPK/TK for innovative drugs. He has also published papers in international  journals such as DMD, EODMT, JSS and JPBA.Having worked in the pharmaceutical R&D field for nearly 10years. Before joining Medicilon, Dr. Jiang held positions in the DMPK/TK and clinical pharmacology departments of well-known Biotech/Pharma/CRO companies (AstraZeneca Dizal Pharma, Covance, ChemPartner), focusing on small and large molecules. Dr. Jiang has been responsible for or involved in supporting hundreds of DMPK projects, including drugs, which have been approved by the Chinese NMPA and the US FDA for clinical research or market entry. Dr. Jiang also holds significant professional affiliations, serving as a youth committee member of the Drug Metabolism Committee of the Chinese Pharmacological Society (CSSX), a committee member of the Drug Metabolism Committee of the Shanghai Pharmacological Society, a youth committee member of the Pharmacology Committee of the Shanghai Pharmaceutical Association, and a member of the International Society for the Study of Xenobiotics (ISSX).

Business Communication
预约商务洽谈

Dr. Peggy Teng, Executive Director BD Operations

Dr. Karsten Holm, Director of Business Development

Dr. Mingzhu Zhang, VP of Business Development